Cargando…
Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan
Urinary tract infection (UTI) is a common health care-associated adverse event and the leading nosocomial complication following pediatric urological surgery. While continuous antimicrobial prophylaxis effectively reduces the risk of UTI following such a surgery, non-adherence is common and represen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000562/ https://www.ncbi.nlm.nih.gov/pubmed/33800757 http://dx.doi.org/10.3390/pharmaceutics13030345 |
_version_ | 1783671026619514880 |
---|---|
author | Saito, Jumpei Miyamoto, Sayaka Yamada, Mayumi Yamatani, Akimasa Ruiz, Fabrice Vallet, Thibault |
author_facet | Saito, Jumpei Miyamoto, Sayaka Yamada, Mayumi Yamatani, Akimasa Ruiz, Fabrice Vallet, Thibault |
author_sort | Saito, Jumpei |
collection | PubMed |
description | Urinary tract infection (UTI) is a common health care-associated adverse event and the leading nosocomial complication following pediatric urological surgery. While continuous antimicrobial prophylaxis effectively reduces the risk of UTI following such a surgery, non-adherence is common and represents a distinct clinical entity that is associated with renal scarring. Acceptability is likely to have a significant impact on patient adherence. Herein we used a validated data-driven approach—the ClinSearch acceptability score test (CAST)—to investigate the acceptability of cefaclor, an oral antibiotic widely used for the prevention of pediatric UTI in Japan. Standardized observer reports were collected for 58 intakes of cefaclor 10% fine granules in patients aged from 0 to 17 years. The medicine was classified as positively accepted on the acceptability reference framework. According to the percentage of the prescribed dose taken reported at the end of the treatment, patients exhibited good adherence to this well-accepted medicine. Nonetheless, requirements for greater dosing frequency or poor acceptability in certain patients could affect adherence. Acceptability should be established to ensure patient adherence to medicines used for long-term prophylaxis and consequently guarantee the safety and efficacy of the treatment. |
format | Online Article Text |
id | pubmed-8000562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80005622021-03-28 Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan Saito, Jumpei Miyamoto, Sayaka Yamada, Mayumi Yamatani, Akimasa Ruiz, Fabrice Vallet, Thibault Pharmaceutics Article Urinary tract infection (UTI) is a common health care-associated adverse event and the leading nosocomial complication following pediatric urological surgery. While continuous antimicrobial prophylaxis effectively reduces the risk of UTI following such a surgery, non-adherence is common and represents a distinct clinical entity that is associated with renal scarring. Acceptability is likely to have a significant impact on patient adherence. Herein we used a validated data-driven approach—the ClinSearch acceptability score test (CAST)—to investigate the acceptability of cefaclor, an oral antibiotic widely used for the prevention of pediatric UTI in Japan. Standardized observer reports were collected for 58 intakes of cefaclor 10% fine granules in patients aged from 0 to 17 years. The medicine was classified as positively accepted on the acceptability reference framework. According to the percentage of the prescribed dose taken reported at the end of the treatment, patients exhibited good adherence to this well-accepted medicine. Nonetheless, requirements for greater dosing frequency or poor acceptability in certain patients could affect adherence. Acceptability should be established to ensure patient adherence to medicines used for long-term prophylaxis and consequently guarantee the safety and efficacy of the treatment. MDPI 2021-03-06 /pmc/articles/PMC8000562/ /pubmed/33800757 http://dx.doi.org/10.3390/pharmaceutics13030345 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Saito, Jumpei Miyamoto, Sayaka Yamada, Mayumi Yamatani, Akimasa Ruiz, Fabrice Vallet, Thibault Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan |
title | Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan |
title_full | Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan |
title_fullStr | Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan |
title_full_unstemmed | Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan |
title_short | Adherence and Acceptability of an Oral Antibiotic Used for the Prevention of Pediatric Urinary Tract Infection in Japan |
title_sort | adherence and acceptability of an oral antibiotic used for the prevention of pediatric urinary tract infection in japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000562/ https://www.ncbi.nlm.nih.gov/pubmed/33800757 http://dx.doi.org/10.3390/pharmaceutics13030345 |
work_keys_str_mv | AT saitojumpei adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan AT miyamotosayaka adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan AT yamadamayumi adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan AT yamataniakimasa adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan AT ruizfabrice adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan AT valletthibault adherenceandacceptabilityofanoralantibioticusedforthepreventionofpediatricurinarytractinfectioninjapan |